Barrett's Esophagus Flashcards

1
Q

What is Barrett’s esophagus

A

Metaplastic columnar epithelium with gastric/intestinal features replacing normal stratified squamous epithelium

US guidelines - biopsy confirmation
UK guidelines - Histological confirmation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the epidemiology of Barrett’s?

A

1.3% in Asian
>50 Y/O
Males
10-15% of patients have esophagitis or longstanding GERD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the risk factors for GERD

A
  1. Long term acid reflux
  2. Age
  3. Males, smoking, caucasian, family history
  4. Hiatal hernia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the pathophysiology of Barrett’s esophagus?

A

Intestinal metaplasia where the squamous mucosa is converted into mucus secreting columnar epithelium with goblet cells

Gatro-esophageal junction is the proximal end of the gastric longitudinal mucosal folds/distal end of esophageal palisading vessels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the clinical presentation of Barrett’s?

A

Asymptomatic but might present with GERD

Long standing gastric reflux reported dysphagia, heartburn and bleeindg

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the complications of Barrett’s?

A
  1. 4bs of ulcers - Bleed, burrow, burst, block
  2. Ulcers penetrate metaplastic epithelium the same way as gastric ulcers
  3. Scarring and strictures
  4. Increased risk of dysplasia and adenocarcinoma
    Divided between
    Non dysplastic - 033%/year
    Low grade dysplasia - 0.7%/year
    High grade dysplasia - 7%/year

High grade dysplasia requires intervention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the investigations for Barrett’s?

A
  1. Endoscopy and histology

2. OGD + Biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the endoscopic results of BE?

A

Endoscopy and histology

Normal - Pale-pink and smooth, SCJ and Z line are the same

Barrett’s - Extension of salmon coloured mucosa into esophagus >1cm proximal to GEJ (SCJ is proximal to the GEJ)

Mucosa has histological confirmation of goblet cells from 8 random biopsies, 4 quadrant biopsies every 2cm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the function of OGD+ biopsy in Barrett’s?

A

OGD + biopsy defines short (<3cm) vs long (≥3cm) segment of Barrett’s.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the indications for OGD+biopsy?

A

Risk factors

  1. Age >50
  2. Male
  3. Caucasian.
  4. Obesity
  5. Smoking
  6. GERD
  7. Hiatal Hernia
  8. Family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the prague c&M criteria

A

Measures the depth of barrett’s during OGD withdrawal (must be careful that the OGD is straight)

The “C” is determined by measuring the distance from the GE junction to the highest location where metaplasia is present around the entire circumference of the esophagus.

The “M” is the distance from the GE junction to the highest location of metaplasia.

The higher the Prague C&M numbers (eg. C3 M5), the more severe the Barrett’s esophagus and the higher the risk of developing cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the biopsy results of the Barrett’s region?

A
1. Gastric cardia-type mucosa
Cardiac mucosa (also called cardia-type or junctional mucosa), which has a foveolar (pitted) surface and glands that are lined exclusively by mucus-secreting cells; these cells resemble normal gastric foveolar cells. 
  1. Atrophic gastric fundic-type mucosa

Atrophic gastric fundic-type epithelium (also called oxyntocardiac epithelium), which has a foveolar surface lined by mucus-secreting cells, and a deeper glandular layer that contains chief and parietal cells; these cells resemble those in the gastric fundus.

  1. Specialised intestinal metaplasia
    (a number of columnar cell types including goblet cells, gastric foveolar-type cells, small intestinal-like cells, and colonic-like columnar cells)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the overview of management of Barrett’s esophagus?

A
  1. Treat reflux
  2. Chemoprevention
  3. Endoscopic surveillance
  4. Resection for high grade dysplasia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is underlying reflux treated?

A
  1. Lifestyle changes
  2. Acidsuppresion (PPIs)
  3. Surgery (Similiar to GERD)

However elimination may halt progression, heal ulcers, prevent strictures but it does not reduce risk of cancer and requires endoscopic surveillance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is chemoprevention administered?

A

High dose PPE + Aspirin (only if patients are not on NSAIDS)

long term therapy to see results (8-9years and above)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the guidelines for endoscopic surveillance

A

Pre-Barrett’s esophagus
Chronic longstanding GERD + risk factors = screening endoscopy

Barrett’s without dysplasia
Repeat OGD with biopsy in 6 months, if negative repeat once every 3 years

BE + LGD
Endoscopic eradication + surveillance
Yearly OGD and biopsy till no dysplasia for 2 biopsies, then repeat OGD every 3 years

BE+HGD
Treat with endoscopic therapy or surgery, or if not intensive surveillance of 3 months for at least a year to detect cancer development

Indeterminate dysplasia
Repeat OGD and biopsy after 8 weeks of therapy, if indefinite repeat in 12 months

17
Q

What is the treatment for high grade dysplasia?

A

Surgical resection

If it is localized with a nodular lesion
Endoscopic mucosal resection/ submucosal dissection

If the lesions are not nodular
Endoscopic radiofrequency ablation for complete eradication

Success rates at 12 months for low grade dysplasia (90%) and high grade dysplasia (81%) are associated risk reduction in disease progression

Last option: Esophagectomy but has high morbidity and mortality